I 
114TH CONGRESS 
2D SESSION 
H. R. 4396 
To support a comprehensive public health response to the heroin and 
prescription drug abuse crisis. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 28, 2016 
Mr. PALLONE introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce, and in addition to the Committees on 
the Judiciary, Ways and Means, and Education and the Workforce, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
A BILL 
To support a comprehensive public health response to the 
heroin and prescription drug abuse crisis. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Heroin and Prescription Drug Abuse Prevention and Re-
duction Act’’. 
(b) TABLE OF CONTENTS.—The table of contents for 
this Act is as follows: 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
Sec. 1. Short title; table of contents. 
TITLE I—PREVENTION 
Sec. 101. Practitioner education. 
Sec. 102. Co-prescribing opioid overdose reversal drugs grant program. 
Sec. 103. Opioid overdose reversal co-prescribing guidelines. 
Sec. 104. Surveillance capacity building. 
TITLE II—CRISIS 
Sec. 201. Grants to support syringe exchange programs. 
Sec. 202. Grant program to reduce drug overdose deaths. 
TITLE III—TREATMENT 
Sec. 301. Expansion of patient limits under waiver. 
Sec. 302. Definitions. 
Sec. 303. Evaluation by assistant Secretary for planning and evaluation. 
Sec. 304. Reauthorization of residential treatment programs for pregnant and 
postpartum women. 
Sec. 305. Pilot program grants for State substance abuse agencies. 
Sec. 306. Evidence-based opioid and heroin treatment and interventions dem-
onstration. 
Sec. 307. Adolescent treatment and recovery services demonstration grant pro-
gram. 
Sec. 308. Strengthening parity in mental health and substance use disorder 
benefits. 
Sec. 309. Study on treatment infrastructure. 
Sec. 310. Substance use disorder professional loan repayment program. 
TITLE IV—RECOVERY 
Sec. 401. National youth recovery initiative. 
Sec. 402. Grants to enhance and expand recovery support services. 
TITLE I—PREVENTION 
SEC. 101. PRACTITIONER EDUCATION. 
(a) EDUCATION REQUIREMENTS.— 
(1) REGISTRATION
CONSIDERATION.—Section 
303(f) of the Controlled Substances Act (21 U.S.C. 
823(f)) is amended by inserting after paragraph (5) 
the following: 
‘‘(6) The applicant’s compliance with the train-
ing requirements described in subsection (g)(3) dur-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
ing any previous period in which the applicant has 
been subject to such training requirements.’’. 
(2) TRAINING REQUIREMENTS.—Section 303(g) 
of the Controlled Substances Act (21 U.S.C. 823(g)) 
is amended by adding at the end the following: 
‘‘(3)(A) To be registered to prescribe or otherwise 
dispense opioids for the treatment of pain, or pain man-
agement, a practitioner described in paragraph (1) shall 
comply with the 12-hour training requirement of subpara-
graph (B) at least once during each 3-year period. 
‘‘(B) The training requirement of this subparagraph 
is that the practitioner has completed not less than 12 
hours of training (through classroom situations, seminars 
at professional society meetings, electronic communica-
tions, or otherwise) with respect to— 
‘‘(i) the treatment and management of opioid- 
dependent patients; 
‘‘(ii) pain management treatment guidelines; 
and 
‘‘(iii) early detection of opioid addiction, includ-
ing through such methods as Screening, Brief Inter-
vention, and Referral to Treatment (SBIRT), 
that is provided by the American Society of Addiction 
Medicine, the American Academy of Addiction Psychiatry, 
the American Medical Association, the American Osteo-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
gram (in this title referred to as the ‘‘grant pro-
gram’’) under which the Secretary shall provide not 
more than a total of 12 grants to eligible entities to 
carry out the activities described in subsection (c). 
(2) ELIGIBLE ENTITY.—For purposes of this 
section, the term ‘‘eligible entity’’ means a federally 
qualified health center (as defined in section 
1861(aa) of the Social Security Act (42 U.S.C. 
1395x(aa))), an opioid treatment program under 
part 8 of title 42, Code of Federal Regulations, or 
section 303(g) of the Controlled Substances Act (21 
U.S.C. 823(g)), a program approved by a State sub-
stance abuse agency, or any other entity that the 
Secretary deems appropriate. 
(3) CO-PRESCRIBING.—For purposes of this 
title, the term ‘‘co-prescribing’’ means, with respect 
to an opioid overdose reversal drug, the practice of 
prescribing such drug in conjunction with an opioid 
prescription for patients at an elevated risk of over-
dose, or in conjunction with an opioid agonist ap-
proved under section 505 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355) for the 
treatment of opioid abuse disorders, or in other cir-
cumstances in which a provider identifies a patient 
at an elevated risk for an intentional or uninten-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
tional drug overdose from heroin or prescription 
opioid therapies. For purposes of the previous sen-
tence, a patient may be at an elevated risk of over-
dose if the patient meets the criteria under the exist-
ing co-prescribing guidelines that the Secretary 
deems appropriate, such as the criteria provided in 
the Opioid Overdose Toolkit published by the Sub-
stance Abuse and Mental Health Services Adminis-
tration. 
(b) APPLICATION.—To be eligible to receive a grant 
under this section, an eligible entity shall submit to the 
Secretary of Health and Human Services, in such form 
and manner as specified by the Secretary, an application 
that describes— 
(1) the extent to which the area to which the 
entity will furnish services through use of the grant 
is experiencing significant morbidity and mortality 
caused by opioid abuse; 
(2) the criteria that will be used to identify eli-
gible patients to participate in such program; and 
(3) how such program will work to try to iden-
tify State, local, or private funding to continue the 
program after expiration of the grant. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(c) USE OF FUNDS.—An eligible entity receiving a 
grant under this section may use the grant for any of the 
following activities: 
(1) To establish a program for co-prescribing 
opioid overdose reversal drugs, such as naloxone. 
(2) To train and provide resources for health 
care providers and pharmacists on the co-prescribing 
of opioid overdose reversal drugs. 
(3) To establish mechanisms and processes, 
consistent with applicable Federal and State privacy 
rules, for tracking patients participating in the pro-
gram described in paragraph (1) and the health out-
comes of such patients. 
(4) To purchase opioid overdose reversal drugs 
for distribution under the program described in 
paragraph (1). 
(5) To offset the co-pays and other cost sharing 
associated with opioid overdose reversal drugs to en-
sure that cost is not a limiting factor for eligible pa-
tients. 
(6) To conduct community outreach, in con-
junction with community-based organizations, de-
signed to raise awareness of co-prescribing practices, 
and the availability of opioid overdose reversal 
drugs. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(7) To establish protocols to connect patients 
who have experienced a drug overdose with appro-
priate treatment, including medication assisted 
treatment and appropriate counseling and behavioral 
therapies. 
(d) EVALUATIONS BY RECIPIENTS.—As a condition 
of receipt of a grant under this section, an eligible entity 
shall, for each year for which the grant is received, submit 
to the Secretary of Health and Human Services informa-
tion on appropriate outcome measures specified by the 
Secretary to assess the outcomes of the program funded 
by the grant, including— 
(1) the number of prescribers trained; 
(2) the number of prescribers who have co-pre-
scribed an opioid overdose reversal drug to at least 
one patient; 
(3) the total number of prescriptions written for 
opioid overdose reversal drugs; 
(4) the percentage of patients at elevated risk 
who received a prescription for an opioid overdose 
reversal drug; 
(5) the number of patients reporting use of an 
opioid overdose reversal drug; and 
(6) any other outcome measures that the Sec-
retary deems appropriate. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(e) REPORTS BY SECRETARY.—For each year of the 
grant program under this section, the Secretary of Health 
and Human Services shall submit to the appropriate com-
mittees of the House of Representatives and of the Senate 
a report aggregating the information received from the 
grant recipients for such year under subsection (d) and 
evaluating the outcomes achieved by the programs funded 
by grants made under this section. 
(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section and 
section 103 $4,000,000 for each of fiscal years 2017 
through 2021. 
SEC. 103. OPIOID OVERDOSE REVERSAL CO-PRESCRIBING 
GUIDELINES. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall establish a grant program under 
which the Secretary shall award grants to eligible State 
entities to develop opioid overdose reversal co-prescribing 
guidelines. 
(b) ELIGIBLE STATE ENTITIES.—For purposes of 
subsection (a), eligible State entities are State depart-
ments of health in conjunction with State medical boards; 
city, county, and local health departments; and community 
stakeholder groups involved in reducing opioid overdose 
deaths. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(2) establishing, in cooperation with the Na-
tional Poison Data System, coroners, and medical 
examiners, a comprehensive national program for 
surveillance of, and reporting to an electronic data-
base on, drug overdose deaths in the United States; 
and 
(3) establishing, in cooperation with the Na-
tional Poison Data System, a comprehensive na-
tional program for surveillance of, and reporting to 
an electronic database on, fatal and nonfatal drug 
overdose occurrences, including epidemiological and 
toxicologic analysis and trends. 
(b) ELIGIBLE ENTITY.—To be eligible to receive a 
grant or cooperative agreement under this section, an enti-
ty shall be— 
(1) a State, local, or tribal government; or 
(2) the National Poison Data System working 
in conjunction with a State, local, or tribal govern-
ment. 
(c) APPLICATION.— 
(1) IN GENERAL.—An eligible entity desiring a 
grant or cooperative agreement under this section 
shall submit to the Secretary an application at such 
time, in such manner, and containing such informa-
tion as the Secretary may require. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(2) CONTENTS.—An application described in 
paragraph (1) shall include— 
(A) a description of the activities to be 
funded through the grant or cooperative agree-
ment; and 
(B) evidence that the eligible entity has the 
capacity to carry out such activities. 
(d) REPORT.—As a condition of receipt of a grant 
or cooperative agreement under this section, an eligible en-
tity shall agree to prepare and submit, not later than 90 
days after the end of the grant or cooperative agreement 
period, a report to the Secretary describing the results of 
the activities supported through the grant or cooperative 
agreement. 
(e) NATIONAL POISON DATA SYSTEM.—In this sec-
tion, the term ‘‘National Poison Data System’’ means the 
system operated by the American Association of Poison 
Control Centers, in partnership with the Centers for Dis-
ease Control and Prevention, for real-time local, State, 
and national electronic reporting, and the corresponding 
database network. 
(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$5,000,000 for each of the fiscal years 2017 through 
2021. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
TITLE II—CRISIS 
SEC. 201. GRANTS TO SUPPORT SYRINGE EXCHANGE PRO-
GRAMS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services may award grants to State, local, and 
tribal governments and community organizations to sup-
port syringe exchange programs. 
(b) USE OF FUNDS.—Grants under subsection (a) 
may be used to support carrying out syringe exchange pro-
grams, including through— 
(1) providing outreach, counseling, health edu-
cation, case management, syringe disposal, and 
other services as determined appropriate by the Sec-
retary of Health and Human Services; and 
(2) providing technical assistance, including 
training and capacity building, to assist the develop-
ment and implementation of syringe exchange pro-
grams. 
(c) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated $15,000,000 for each of fis-
cal years 2017 through 2021 to carry out this section, of 
which— 
(1) at least 15 percent shall be for syringe ex-
change programs that have been in operation for 
less than 3 years; and 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(2) 5 percent shall be for technical assistance 
under subsection (b)(2). 
SEC. 202. GRANT PROGRAM TO REDUCE DRUG OVERDOSE 
DEATHS. 
(a) PROGRAM
AUTHORIZED.—The Secretary of 
Health and Human Services, acting through the Adminis-
trator of the Substance Abuse and Mental Health Services 
Administration, shall award grants or enter into coopera-
tive agreements with eligible entities to enable the eligible 
entities to reduce deaths occurring from overdoses of 
drugs. 
(b) ELIGIBLE ENTITIES.—To be eligible to receive a 
grant or cooperative agreement under this section, an enti-
ty shall be a partnership between any of the following: a 
State, local, or tribal government, a correctional institu-
tion, a law enforcement agency, a community agency, a 
professional organization in the field of poison control and 
surveillance, or a private nonprofit organization. 
(c) APPLICATION.— 
(1) IN GENERAL.—An eligible entity desiring a 
grant or cooperative agreement under this section 
shall submit to the Secretary of Health and Human 
Services an application at such time, in such man-
ner, and containing such information as the Sec-
retary may require. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(2) CONTENTS.—An application under para-
graph (1) shall include— 
(A) a description of the activities to be 
funded through the grant or cooperative agree-
ment; and 
(B) evidence that the eligible entity has the 
capacity to carry out such activities. 
(d) PRIORITY.—In entering into grants and coopera-
tive agreements under subsection (a), the Secretary of 
Health and Human Services shall give priority to eligible 
entities that— 
(1) include a public health agency or commu-
nity-based organization; and 
(2) have expertise in preventing deaths occur-
ring from overdoses of drugs in populations at high 
risk of such deaths. 
(e) ELIGIBLE ACTIVITIES.—As a condition of receipt 
of a grant or cooperative agreement under this section, 
an eligible entity shall agree to use the grant or coopera-
tive agreement to do each of the following: 
(1) Purchase and distribute the drug naloxone 
or a similarly effective medication. 
(2) Carry out one or more of the following ac-
tivities: 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(A) Educating prescribers and pharmacists 
about overdose prevention and naloxone pre-
scription, or prescriptions of a similarly effec-
tive medication. 
(B) Training first responders, other indi-
viduals in a position to respond to an overdose, 
and law enforcement and corrections officials on 
the effective response to individuals who have 
overdosed on drugs. Training pursuant to this 
subparagraph may include any activity that is 
educational, instructional, or consultative in na-
ture, and may include volunteer training, 
awareness building exercises, outreach to indi-
viduals who are at-risk of a drug overdose, and 
distribution of educational materials. 
(C) Implementing and enhancing programs 
to provide overdose prevention, recognition, 
treatment, and response to individuals in need 
of such services. 
(D) Educating the public and providing 
outreach to the public about overdose preven-
tion and naloxone prescriptions, or prescriptions 
of other similarly effective medications. 
(f) COORDINATING CENTER.— 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(1) ESTABLISHMENT.—The Secretary of Health 
and Human Services shall establish and provide for 
the operation of a coordinating center responsible 
for— 
(A) collecting, compiling, and dissemi-
nating data on the programs and activities 
under this section, including tracking and eval-
uating the distribution and use of naloxone and 
other similarly effective medication; 
(B) evaluating such data and, based on 
such evaluation, developing best practices for 
preventing 
deaths 
occurring 
from 
drug 
overdoses; 
(C) making such best practices specific to 
the type of community involved; 
(D) coordinating and harmonizing data 
collection measures; 
(E) evaluating the effects of the program 
on overdose rates; and 
(F) education and outreach to the public 
about overdose prevention and prescription of 
naloxone and other similarly effective medica-
tion. 
(2) REPORTS TO CENTER.—As a condition on 
receipt of a grant or cooperative agreement under 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
this section, an eligible entity shall agree to prepare 
and submit, not later than 90 days after the end of 
the award period, a report to such coordinating cen-
ter and the Secretary of Health and Human Services 
describing the results of the activities supported 
through the grant or cooperative agreement. 
(g) DURATION.—The period of a grant or cooperative 
agreement under this section shall be 4 years. 
(h) DEFINITION.—In this part, the term ‘‘drug’’— 
(1) means a drug, as defined in section 201 of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 321); and 
(2) includes controlled substances, as defined in 
section 102 of the Controlled Substances Act (21 
U.S.C. 802). 
(i) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated $20,000,000 to carry out 
this section for each of the fiscal years 2017 through 
2021. 
TITLE III—TREATMENT 
SEC. 301. EXPANSION OF PATIENT LIMITS UNDER WAIVER. 
Section 303(g)(2)(B) of the Controlled Substances 
Act (21 U.S.C. 823(g)(2)(B)) is amended— 
(1) in clause (i), by striking ‘‘physician’’ and in-
serting ‘‘practitioner’’; 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(2) in clause (iii)— 
(A) by striking ‘‘30’’ and inserting ‘‘100’’; 
and 
(B) by striking ‘‘, unless, not sooner’’ and 
all that follows through the end and inserting a 
period; and 
(3) by inserting at the end the following new 
clause: 
‘‘(iv) Not earlier than 1 year after the date 
on which a qualifying practitioner obtained an 
initial waiver pursuant to clause (iii), the quali-
fying practitioner may submit a second notifica-
tion to the Secretary of the need and intent of 
the qualifying practitioner to treat an unlimited 
number of patients, if the qualifying practi-
tioner— 
‘‘(I)(aa) satisfies the requirements of 
item (aa), (bb), (cc), or (dd) of subpara-
graph (G)(ii)(I); and 
‘‘(bb) agrees to fully participate in the 
Prescription Drug Monitoring Program of 
the State in which the qualifying practi-
tioner is licensed, pursuant to applicable 
State guidelines; or 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(II)(aa) satisfies the requirements of 
item (ee), (ff), or (gg) of subparagraph 
(G)(ii)(I); 
‘‘(bb) agrees to fully participate in the 
Prescription Drug Monitoring Program of 
the State in which the qualifying practi-
tioner is licensed, pursuant to applicable 
State guidelines; 
‘‘(cc) practices in a qualified practice 
setting; and 
‘‘(dd) has completed not less than 24 
hours of training (through classroom situa-
tions, seminars at professional society 
meetings, electronic communications, or 
otherwise) with respect to the treatment 
and management of opiate-dependent pa-
tients for substance use disorders provided 
by the American Society of Addiction Med-
icine, the American Academy of Addiction 
Psychiatry, the American Medical Associa-
tion, the American Osteopathic Associa-
tion, the American Psychiatric Association, 
or any other organization that the Sec-
retary determines is appropriate for pur-
poses of this subclause.’’. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
SEC. 302. DEFINITIONS. 
Section 303(g)(2)(G) of the Controlled Substances 
Act (21 U.S.C. 823(g)(2)(G)) is amended— 
(1) by striking clause (ii) and inserting the fol-
lowing: 
‘‘(ii) The term ‘qualifying practitioner’ 
means the following: 
‘‘(I) A physician who is licensed under 
State law and who meets 1 or more of the 
following conditions: 
‘‘(aa) The physician holds a 
board certification in addiction psychi-
atry from the American Board of 
Medical Specialties. 
‘‘(bb) The physician holds an ad-
diction certification from the Amer-
ican Society of Addiction Medicine. 
‘‘(cc) The physician holds a 
board certification in addiction medi-
cine from the American Osteopathic 
Association. 
‘‘(dd) The physician holds a 
board certification from the American 
Board of Addiction Medicine. 
‘‘(ee) The physician has com-
pleted not less than 8 hours of train-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
ing (through classroom situations, 
seminar at professional society meet-
ings, electronic communications, or 
otherwise) with respect to the treat-
ment and management of opiate-de-
pendent patients for substance use 
disorders provided by the American 
Society of Addiction Medicine, the 
American Academy of Addiction Psy-
chiatry, the American Medical Asso-
ciation, the American Osteopathic As-
sociation, the American Psychiatric 
Association, or any other organization 
that the Secretary determines is ap-
propriate for purposes of this sub-
clause. 
‘‘(ff) The physician has partici-
pated as an investigator in 1 or more 
clinical trials leading to the approval 
of a narcotic drug in schedule III, IV, 
or V for maintenance or detoxification 
treatment, as demonstrated by a 
statement submitted to the Secretary 
by this sponsor of such approved 
drug. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(gg) The physician has such 
other training or experience as the 
Secretary determines will demonstrate 
the ability of the physician to treat 
and manage opiate-dependent pa-
tients. 
‘‘(II) A nurse practitioner or physi-
cian assistant who is licensed under State 
law and meets all of the following condi-
tions: 
‘‘(aa) The nurse practitioner or 
physician assistant is licensed under 
State law to prescribe schedule III, 
IV, or V medications for pain. 
‘‘(bb) The nurse practitioner or 
physician assistant satisfies 1 or more 
of the following: 
‘‘(AA) Has completed not 
fewer than 24 hours of training 
(through 
classroom 
situations, 
seminar at professional society 
meetings, electronic communica-
tions, or otherwise) with respect 
to the treatment and manage-
ment of opiate-dependent pa-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
tients for substance use disorders 
provided by the American Society 
of Addiction Medicine, the Amer-
ican Academy of Addiction Psy-
chiatry, the American Medical 
Association, the American Osteo-
pathic Association, the American 
Psychiatric Association, or any 
other organization that the Sec-
retary determines is appropriate 
for purposes of this subclause. 
‘‘(BB) Has such other train-
ing or experience as the Sec-
retary 
determines 
will 
dem-
onstrate the ability of the nurse 
practitioner or physician assist-
ant to treat and manage opiate- 
dependent patients. 
‘‘(cc) The nurse practitioner or 
physician assistant practices within 
the scope of their State license, in-
cluding compliance with any super-
vision or collaboration requirements 
under State law. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(dd) The nurse practitioner or 
physician assistant practice in a quali-
fied practice setting.’’; and 
(2) by adding at the end the following: 
‘‘(iii) The term ‘qualified practice setting’ 
means 1 or more of the following treatment set-
tings: 
‘‘(I) A National Committee for Qual-
ity Assurance-recognized Patient-Centered 
Medical Home or Patient-Centered Spe-
cialty Practice. 
‘‘(II) A Centers for Medicaid & Medi-
care Services-recognized Accountable Care 
Organization. 
‘‘(III) A clinical facility administered 
by the Department of Veterans Affairs, 
Department of Defense, or Indian Health 
Service. 
‘‘(IV) A Behavioral Health Home ac-
credited by the Joint Commission. 
‘‘(V) A Federally-qualified health cen-
ter (as defined in section 1905(l)(2)(B) of 
the 
Social 
Security 
Act 
(42 
U.S.C. 
1396d(l)(2)(B))) or a Federally-qualified 
health center look-alike. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(VI) A Substance Abuse and Mental 
Health Services-certified Opioid Treatment 
Program. 
‘‘(VII) A clinical program of a State 
or Federal jail, prison, or other facility 
where individuals are incarcerated. 
‘‘(VIII) A clinic that demonstrates 
compliance with the Model Policy on 
DATA 2000 and Treatment of Opioid Ad-
diction in the Medical Office issued by the 
Federation of State Medical Boards. 
‘‘(IX) A treatment setting that is part 
of an Accreditation Council for Graduate 
Medical Education, American Association 
of Colleges of Osteopathic Medicine, or 
American Osteopathic Association-accred-
ited residency or fellowship training pro-
gram. 
‘‘(X) Any other practice setting ap-
proved by a State regulatory board, State 
substance abuse agency, or State Medicaid 
Plan to provide addiction treatment serv-
ices. 
‘‘(XI) Any other practice setting ap-
proved by the Secretary.’’. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
SEC. 303. EVALUATION BY ASSISTANT SECRETARY FOR 
PLANNING AND EVALUATION. 
Two years after the date on which the first notifica-
tion under clause (iv) of section 303(g)(2)(B) of the Con-
trolled Substances Act (21 U.S.C. 823(g)(2)(B)), as added 
by section 301, is received by the Secretary of Health and 
Human Services, the Assistant Secretary for Planning and 
Evaluation shall initiate an evaluation of the effectiveness 
of the amendments made by sections 301 and 302, which 
shall include an evaluation of— 
(1) any changes in the availability and use of 
medication-assisted treatment for opioid addiction; 
(2) the quality of medication-assisted treatment 
programs; 
(3) the integration of medication-assisted treat-
ment with routine healthcare services; 
(4) diversion of opioid addiction treatment 
medication; 
(5) changes in State or local policies and legis-
lation relating to opioid addiction treatment; 
(6) the use of nurse practitioners and physician 
assistants who prescribe opioid addiction medication; 
(7) the use of Prescription Drug Monitoring 
Programs by waived practitioners to maximize safety 
of patient care and prevent diversion of opioid addic-
tion medication; 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(8) the findings of the Drug Enforcement Ad-
ministration inspections of waived practitioners, in-
cluding the frequency with which the Drug Enforce-
ment Administration finds no documentation of ac-
cess to behavioral health services; and 
(9) the effectiveness of cross-agency collabora-
tion between Department of Health and Human 
Services and the Drug Enforcement Administration 
for expanding effective opioid addiction treatment. 
SEC. 304. REAUTHORIZATION OF RESIDENTIAL TREAT-
MENT 
PROGRAMS 
FOR 
PREGNANT 
AND 
POSTPARTUM WOMEN. 
Section 508 of the Public Health Service Act (42 
U.S.C. 290bb–1) is amended— 
(1) in subsection (p), by inserting ‘‘(other than 
subsection (r))’’ after ‘‘section’’; and 
(2) in subsection (r), by striking ‘‘such sums’’ 
and all that follows through ‘‘2003’’ and inserting 
‘‘$40,000,000 for each of fiscal years 2017 through 
2021’’. 
SEC. 305. PILOT PROGRAM GRANTS FOR STATE SUBSTANCE 
ABUSE AGENCIES. 
(a) IN GENERAL.—Section 508 of the Public Health 
Service Act (42 U.S.C. 290bb–1) is amended— 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
(1) by redesignating subsection (r), as amended 
by section 304, as subsection (s); and 
(2) by inserting after subsection (q) the fol-
lowing new subsection: 
‘‘(r) PILOT
PROGRAM
FOR
STATE
SUBSTANCE 
ABUSE AGENCIES.— 
‘‘(1) IN GENERAL.—From amounts made avail-
able under subsection (s), the Director of the Center 
for Substance Abuse Treatment shall carry out a 
pilot program under which competitive grants are 
made by the Director to State substance abuse agen-
cies to— 
‘‘(A) enhance flexibility in the use of funds 
designed to support family-based services for 
pregnant and postpartum women with a pri-
mary diagnosis of a substance use disorder, in-
cluding opioid use disorders; 
‘‘(B) help State substance abuse agencies 
address identified gaps in services furnished to 
such women along the continuum of care, in-
cluding services provided to women in non-resi-
dential based settings; and 
‘‘(C) promote a coordinated, effective, and 
efficient State system managed by State sub-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
stance abuse agencies by encouraging new ap-
proaches and models of service delivery. 
‘‘(2) REQUIREMENTS.—In carrying out the 
pilot program under this subsection, the Director 
shall— 
‘‘(A) require State substance abuse agen-
cies to submit to the Director applications, in 
such form and manner and containing such in-
formation as specified by the Director, to be eli-
gible to receive a grant under the program; 
‘‘(B) identify, based on such submitted ap-
plications, State substance abuse agencies that 
are eligible for such grants; 
‘‘(C) require services proposed to be fur-
nished through such a grant to support family- 
based treatment and other services for pregnant 
and postpartum women with a primary diag-
nosis of a substance use disorder, including 
opioid use disorders; 
‘‘(D) not require that services furnished 
through such a grant be provided solely to 
women that reside in facilities; 
‘‘(E) not require that grant recipients 
under the program make available through use 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
of the grant all services described in subsection 
(d); and 
‘‘(F) consider not applying requirements 
described in paragraphs (1) and (2) of sub-
section (f) to applicants, depending on the cir-
cumstances of the applicant. 
‘‘(3) REQUIRED SERVICES.— 
‘‘(A) IN
GENERAL.—The Director shall 
specify a minimum set of services required to be 
made available to eligible women through a 
grant awarded under the pilot program under 
this subsection. Such minimum set— 
‘‘(i) shall include requirements de-
scribed in subsection (c) and be based on 
the recommendations submitted under sub-
paragraph (B); and 
‘‘(ii) may be selected from among the 
services described in subsection (d) and in-
clude other services as appropriate. 
‘‘(B) STAKEHOLDER INPUT.—The Director 
shall convene and solicit recommendations from 
stakeholders, including State substance abuse 
agencies, health care providers, persons in re-
covery from substance abuse, and other appro-
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
priate individuals, for the minimum set of serv-
ices described in subparagraph (A). 
‘‘(4) DURATION.—The pilot program under this 
subsection shall not exceed 5 years. 
‘‘(5) EVALUATION
AND
REPORT
TO
CON-
GRESS.—The Director of the Center for Behavioral 
Health Statistics and Quality shall fund an evalua-
tion of the pilot program at the conclusion of the 
first grant cycle funded by the pilot program. The 
Director of the Center for Behavioral Health Statis-
tics and Quality, in coordination with the Director of 
the Center for Substance Abuse Treatment shall 
submit to the relevant committees of jurisdiction of 
the House of Representatives and the Senate a re-
port on such evaluation. The report shall include at 
a minimum outcomes information from the pilot pro-
gram, including any resulting reductions in the use 
of alcohol and other drugs; engagement in treatment 
services; retention in the appropriate level and dura-
tion of services; increased access to the use of medi-
cations approved by the Food and Drug Administra-
tion for the treatment of substance use disorders in 
combination with counseling; and other appropriate 
measures. 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(6) STATE SUBSTANCE ABUSE AGENCIES DE-
FINED.—For purposes of this subsection, the term 
‘State substance abuse agency’ means, with respect 
to a State, the agency in such State that manages 
the Substance Abuse Prevention and Treatment 
Block Grant under part B of title XIX.’’. 
(b) FUNDING.—Subsection (s) of section 508 of the 
Public Health Service Act (42 U.S.C. 290bb–1), as 
amended by section 304 and redesignated by subsection 
(a), is further amended by adding at the end the following 
new sentence: ‘‘Of the amounts made available for a year 
pursuant to the previous sentence to carry out this section, 
not more than 25 percent of such amounts shall be made 
available for such year to carry out subsection (r), other 
than paragraph (5) of such subsection.’’. 
SEC. 306. EVIDENCE-BASED OPIOID AND HEROIN TREAT-
MENT 
AND 
INTERVENTIONS 
DEMONSTRA-
TION. 
Subpart 1 of part B of title V of the Public Health 
Service Act (42 U.S.C. 290bb et seq.) is amended— 
(1) by redesignating section 514 (42 U.S.C. 
290bb–9), as added by section 3632 of the Meth-
amphetamine Anti-Proliferation Act of 2000 (Public 
Law 106–310; 114 Stat. 1236), as section 514B; 
and 
VerDate Sep 11 2014 
02:20 Jan 29, 2016
Jkt 059200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H4396.IH
H4396
emcdonald on DSK67QTVN1PROD with BILLS